FIELD: pharmacology.
SUBSTANCE: invention relates to compositions for prevention or treatment of diseases associated with human papillomavirus (HPV) type 16. The presented compositions comprise one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15, and their antisense nucleotide sequences, as an active ingredient. A nucleotide is a short interfering RNA (siRNA), a short hairpin RNA (shRNA), or an antisense oligonucleotide (ASO).
EFFECT: invention can be used to treat cancer, such as cervical or vaginal cancer.
6 cl, 17 dwg, 4 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING CANCER ASSOCIATED WITH HPV INFECTION | 2017 |
|
RU2664466C1 |
| VECTORS FOR MULTIPLE GENE EXPRESSION | 2008 |
|
RU2462513C2 |
| PAPILLOMAVIRUS E2 POLYPEPTIDES USED FOR VACCINATION | 2008 |
|
RU2482189C2 |
| IMMUNOGENIC COMPOSITION BASED ON RECOMBINANT PROTEINS E6-CBD AND E7-CBD FOR THE TREATMENT OF MALIGNANT NEOPLASMS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS TYPE 16 | 2023 |
|
RU2805482C1 |
| VACCINE COMPOSITION | 2014 |
|
RU2684211C2 |
| PEPTIDE POSSESSING CAPACITY TO BIND CASEIN KINASE II (CKII) PHOSPHORYLATING SITE AND TO INHIBIT PHOSPHORYLATION, FUSED POLYPEPTIDE, THEIR USING | 2002 |
|
RU2290410C2 |
| EXPRESSING VECTOR (VARIANTS) | 1995 |
|
RU2177999C2 |
| COMBINATION OF POXVIRUS ENCODING HUMAN PAPILLOMA VIRUS POLYPEPTIDES, AND IL-2 WITH ANTI-PD-L1 ANTIBODY | 2020 |
|
RU2824962C1 |
| OPTIMISED EXPRESSION OF HPV 58 L1 IN YEAST | 2004 |
|
RU2370538C2 |
| 3,3'-DIINDOLYLMETHANE (METINDOL)-BASE VAGINAL SUPPOSITORY | 2006 |
|
RU2318510C1 |
